Intestinal Absorptive Anti-Tumor Agent

• US 20090136577A1
• Filed: 04/05/2006
• Published: 05/28/2009
• Est. Priority Date: 04/06/2005
• Status: Active Grant

• Current Assignee: Kabushiki Kaisha Sangi
• Original Assignee: Kabushiki Kaisha Sangi
• Inventors: Atsumi, Kiminori, Kikukawa, Keiichiro, Sakuma, Shuji
• Granted Patent: US 8,293,274 B2
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 31/02 Halogenated hydrocarbons
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 31/475 having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine vincamine A61K31/4375
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/48 acting on peptide bonds (3.4)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/143 with inorganic compounds
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/167 with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface with further drug-free outer coating A61K9/5073
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia

Abstract

An objective of the present invention is to provide intestinal absorptive antitumor agents with an excellent intestinal absorptive effect by using injectable antitumor agents. In the intestinal absorptive pharmaceutical agents of the present invention, antitumor components that can be used only as injections are supported by hydroxyapatite particles.

Claims

1. An intestinal absorptive antitumor agent, in which an injectable antitumor component is supported by hydroxyapatite particles.

2. The intestinal absorptive antitumor agent of claim 1, wherein said hydroxyapatite has a maximum particle size of 10 μ

m or less.

3. The intestinal absorptive antitumor agent of claim 1, wherein said hydroxyapatite has a maximum particle size of 0.5 μ

m or less.

4. The intestinal absorptive antitumor agent of claim 1, wherein said hydroxyapatite has a maximum particle size of 0.1 μ

m or less.

5. The intestinal absorptive antitumor agent of any claim 1, wherein the content of said hydroxyapatite is 0.5 to 5000 weight percent of the injectable antitumor component.

6. The intestinal absorptive antitumor agent of claim 1, wherein said injectable antitumor component is a platinum preparation, cytokine, alkylating agent, antimetabolite, antitumor antibiotic, plant preparation, immunotherapeutic agent, kinase inhibitor, enzyme preparation, histamine A derivative, aminopeptidase, mannitol derivative, bisdioxopiperazine derivative, inhibitor of recurrent bladder tumor, or therapeutic agent for cancer pain.

7. The intestinal absorptive antitumor agent of claim 6, wherein said platinum preparation is selected from the group consisting of cisplatin, carboplatin, and nedaplatin;

said cytokine is an interferon;

said alkylating agent is selected from the group consisting of ranimustine, nimustine hydrochloride, ifosfamide, dacarbazine, and thiotepa;

said antimetabolite is selected from the group consisting of gemcitabine hydrochloride, cytarabine, enocitabine, fludarabine phosphate, calcium levofolinate, vincristine sulfate, and vinblastine sulfate;

said antitumor antibiotic is selected from the group consisting of peplomycin sulfate, pirarubicin hydrochloride, zinostatin stimalamer, idarubicin hydrochloride, mitomycin C, bleomycin hydrochloride, doxorubicin hydrochloride, daunorubicin hydrochloride, and epirubicin hydrochloride;

said plant preparation is selected from the group consisting of vindesine sulfate, vinorelbine ditartrate, irinotecan hydrochloride, nogitecan hydrochloride, docetaxel hydrate, and paclitaxel.

8. The intestinal absorptive antitumor agent of claim 1, wherein said hydroxyapatite is an amorphous hydroxyapatite.

10. A method for treating a tumor, which comprises administering an effective amount of the intestinal absorptive antitumor agent of claim 1 to a patient in need of prevention or treatment of the tumor.

9. Use of a hydroxyapatite particle that supports an injectable antitumor component for preparing an intestinal absorptive antitumor agent.